Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Germany's Merck under formal investigation in France over thyroid drug

Published 19/10/2022, 10:55
© Reuters. FILE PHOTO: A cyclist drives past a logo of drugs and chemicals group Merck KGaA in Darmstadt, Germany January 28, 2016.  REUTERS/Ralph Orlowski
MRK
-
MRCG
-
FORTY
-
MKKGY
-
MRCK34
-

PARIS (Reuters) - German drugmaker Merck KGaA said on Wednesday it had been placed under formal investigation by a French court for possibly issuing misleading information regarding its thyroid drug product Levothyrox.

The ruling by a judge in the French city of Marseille did not concern in any way the new formula for the Levothyrox product, but the way the company provided information when changing from the old to the new formula, Merck said in a statement.

It is part of criminal proceedings launched in March 2018.

Merck has already been condemned in civil litigations for not providing sufficient information when changing the drug's formulas.

Mario-Pierre Stasi, the lawyer for Merck, said on Wednesay the company would continue to co-operate with authorities on the matter and that full legal proceedings must be allowed to run their course.

Merck also confirmed that the Marseille judge had placed the company under court supervision, asking it to pay a deposit of 4.3 million euros and provide a banking guarantee of up to 7 millon euros, which its lawyer said was "totally unjustified".

In March 2022, France's highest court, the Cour de Cassation, confirmed a 2020 Lyon appeal court ruling ordering Merck to pay 1,000 euros ($982.30) each to compensate more than 3,300 people suffering from thyroid problems in France after it changed the formula of the drug in 2017.

The plaintiffs had accused Merck of not providing sufficient information regarding changes to the product.

They had said Merck’s decision to remove lactose from the drug to make it easier to handle had resulted in side effects such as memory loss, weight gain and palpitations.

© Reuters. FILE PHOTO: A cyclist drives past a logo of drugs and chemicals group Merck KGaA in Darmstadt, Germany January 28, 2016.  REUTERS/Ralph Orlowski

($1 = 1.0180 euros)

(The photo filed for this story has been corrected with the correct logo.)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.